Current Management of Refractory Germ Cell Tumors

[1] Siegel RL(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-30

[2] Miller KD(2003)Increasing incidence of testicular cancer worldwide: a review J Urol Jul 170 5-11

[3] Jemal A(2018)Testicular cancer: epidemiology, diagnosis, and management Med Clin North Am 102 251-264

[4] Huyghe E(2013)Classification, epidemiology and therapies for testicular germ cell tumours Int J Dev Biol 57 133-139

[5] Matsuda T(1997)International Germ Cell Cancer Collaborative Group J Clin Oncol 15 594-603

[6] Thonneau P(2008)Medical treatment of advanced testicular cancer JAMA. 299 672-684

[7] Smith ZL(2007)Genito-Urinary Group of the French Federation of Cancer Center (GETUG T93BP). Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP) Ann Oncol 18 917-924

[8] Werntz RP(2006)Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: an update based on meta-analysis Eur J Cancer 42 820-826

[9] Eggener SE(2017)Prognostic Factors and treatment results after bleomycin, etoposide, and cisplatin in germ cell cancer: a population-based study Eur Urol 71 290-298

[10] Vasdev N(2018)Management of refractory germ cell cancer Am Soc Clin Oncol Educ Book 38 324-329

[1] Siegel RL(2020)Cancer statistics, 2020 CA Cancer J Clin 70 7-30

[2] Miller KD(2003)Increasing incidence of testicular cancer worldwide: a review J Urol Jul 170 5-11

[3] Jemal A(2018)Testicular cancer: epidemiology, diagnosis, and management Med Clin North Am 102 251-264

[4] Huyghe E(2013)Classification, epidemiology and therapies for testicular germ cell tumours Int J Dev Biol 57 133-139

[5] Matsuda T(1997)International Germ Cell Cancer Collaborative Group J Clin Oncol 15 594-603

[6] Thonneau P(2008)Medical treatment of advanced testicular cancer JAMA. 299 672-684

[7] Smith ZL(2007)Genito-Urinary Group of the French Federation of Cancer Center (GETUG T93BP). Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP) Ann Oncol 18 917-924

[8] Werntz RP(2006)Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: an update based on meta-analysis Eur J Cancer 42 820-826

[9] Eggener SE(2017)Prognostic Factors and treatment results after bleomycin, etoposide, and cisplatin in germ cell cancer: a population-based study Eur Urol 71 290-298

[10] Vasdev N(2018)Management of refractory germ cell cancer Am Soc Clin Oncol Educ Book 38 324-329